Evidence map›Paper›PMID 30567989›Full record

ArticleJournal of virology2019

Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.

Lin Deng, Xiang Gan, Masahiko Ito, Ming Chen, Hussein H Aly, Chieko Matsui, Takayuki Abe, Koichi Watashi, Takaji Wakita, Tetsuro Suzuki and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Exosomes as therapeutic vehicles in liver diseases.Annals of translational medicine · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Lin DengDivision of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan denglm@med.kobe-u.ac.jp hotta@kobe-u.ac.jp.
Xiang GanInstitute of Biochemistry and Molecular Biology, Hubei University, Wuhan, Hubei, China.
Masahiko ItoDepartment of Virology and Parasitology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Ming ChenDepartment of Vaccine and Drug Development, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Hussein H AlyDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Chieko MatsuiDivision of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Takayuki AbeDivision of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Koichi WatashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Takaji WakitaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Tetsuro SuzukiDepartment of Virology and Parasitology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Toru OkamotoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Yoshiharu MatsuuraDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Masashi MizokamiResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Ikuo ShojiDivision of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID 0000-0002-0730-4379
Hak HottaDepartment of Vaccine and Drug Development, Kobe University Graduate School of Health Sciences, Kobe, Japan denglm@med.kobe-u.ac.jp hotta@kobe-u.ac.jp.
Kobe University · JPNational Institute of Infectious Diseases · JPHamamatsu University School of Medicine · JPThe University of Osaka · JPHubei University · CNKonan Women's University · JPNational Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection is a major risk factor for the development of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). A growing body of evidence suggests that HBV X protein (HBx) plays a crucial role in viral replication and HCC development. Here, we identified peroxiredoxin 1 (Prdx1), a cellular hydrogen peroxide scavenger, as a novel HBx-interacting protein. Coimmunoprecipitation analysis coupled with site-directed mutagenesis revealed that the region from amino acids 17 to 20 of the HBx, particularly HBx Cys

Indexed as

Antigens, NeoplasmCell Line, TumorEnhancer Elements, GeneticExosome Multienzyme Ribonuclease ComplexExosomesHepatitis BHepatitis B virusHep G2 CellsHost-Pathogen InteractionsHumansImmunoprecipitationKineticsPeroxiredoxinsPromoter Regions, GeneticRNA-Binding ProteinsRNA, ViralAntigens, NeoplasmEXOSC5 protein, humanExosome Multienzyme Ribonuclease Complexhepatitis B virus X proteinPeroxiredoxinsPRDX1 protein, humanRNA-Binding ProteinsRNA, ViralTrans-ActivatorsViral Regulatory and Accessory ProteinsHBxhepatitis B virusPrdx1

Identifiers

PMID30567989
PMCPMC6401444
OpenAlexW2906097536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.